ArticleNeurobiology of disease2007
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Article in Neurobiology of disease, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 69 citations in OpenAlex.
- Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models.International journal of molecular sciences · 2024Review
- Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.Journal of Parkinson's disease · 2024Article
- Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.Biomolecules · 2023Article
- Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.Movement disorders : official journal of the Movement Disorder Society · 2023Article
- Dopamine-independent development and maintenance of mouse striatal medium spiny neuron dendritic spines.Neurobiology of disease · 2023Article
- PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.International journal of molecular sciences · 2023Article
- A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.Neurobiology of disease · 2022Article
- Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia.Communications biology · 2021Article
- Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.Molecular neurobiology · 2019Article
- Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.Molecular neurobiology · 2019Article
- Article
- Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- Effects of a combination treatment of KD5040 andBMC complementary and alternative medicine · 2017Article
- Striatal But Not Extrastriatal Dopamine Receptors Are Critical to Dopaminergic Motor Stimulation.Frontiers in pharmacology · 2017Article
- Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.Experimental neurology · 2016Article
- L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.Brain research · 2015Article
- Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia.Neurobiology of disease · 2015Article
- Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic output.Journal of neurophysiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
L-DOPA-induced dyskinesia (LID) is one of the main limitations of long term L-DOPA use in Parkinson's disease (PD) patients. We show that chronic L-DOPA treatment induces novel dyskinetic behaviors in aphakia mouse with selective nigrostriatal deficit mimicking PD. The stereotypical abnormal involuntary movements were induced by dopamine receptor agonists and attenuated by antidyskinetic agents. The development of LID was accompanied by preprodynorphin and preproenkephalin expression changes in the denervated dorsal striatum. Increased FosB-expression was also noted in the dorsal striatum. In addition, FosB expression was noted in the pedunculopontine nucleus and the zona incerta, structures previously not examined in the setting of LID. The aphakia mouse is a novel genetic model with behavioral and biochemical characteristics consistent with those of PD dyskinesia and provides a more consistent, convenient, and physiologic model than toxic lesion models to study the mechanism of LID and to test therapeutic approaches for LID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.